

## **AusCann Successful in Bid to Allow for the Supply of Neuvis® for the Tasmanian Department of Health**

### **Key Highlight**

- AusCann has entered into an agreement to allow for the supply of pharmaceutical cannabis products for the Tasmanian Department of Health;
- The agreement follows a successful bid in response to a Request for Tender issued by the Department of Health for the supply of pre-packaged pharmaceutical products to the Tasmania Health Service (THS), Ambulance Tasmania (AT) and other Tasmanian Government health centres;
- The awarded products to be made available for supply, subject to receipt of official purchase orders, include the Company's proprietary Neuvis® THC/CBD 1:1 oral capsule's in 2.5mg and 10mg concentrations.

---

**1 July 2021 - AusCann Group Holdings Limited** (ASX: AC8) ('AusCann' or 'the Company') is pleased to announce that AusCann has entered into an agreement to allow for the supply of pre-packaged pharmaceutical cannabis products for the Tasmanian Department of Health (DoH).

Subject to receipt of official purchase orders, the awarded products can be supplied to hospitals within the Tasmania Health Service (THS), Ambulance Tasmania (AT), and other Tasmanian Government health centres, hospitals or organisations with a contracted pharmacy arrangement with the DoH, the THS or AT.

Tasmania is the only jurisdiction in Australia where General Practitioners (GP's) are unable to prescribe medicinal cannabis to patients. However, changes are being made to improve the Controlled Access Scheme in the State, which will include authorising Tasmanian GP's to prescribe medical cannabis products and allowing more pharmacies across the State to be able to dispense these products.

This is expected to align access to unapproved medicinal cannabis products in Tasmania with other Australian jurisdictions, providing additional options for health practitioners and patients in Tasmania from 1 July 2021.

With the ongoing changes to the Tasmanian Controlled Access Scheme at present, the quantum of product supplied under this agreement cannot be forecasted, and as such, is not expected to be material in the near term.

Mr Layton Mills, CEO of AusCann said: "We're delighted that AusCann has been accepted as a supplier of pharmaceutical cannabis products to health centres and hospitals in Tasmania. This development, along with recent confirmation that selected Australian health funds allow our Neuvis® hard-shell capsules in their reimbursement programmes, further supports the Company's commitment to providing reliable, stable and standardised cannabinoid-derived therapeutic products to patients in Australia."

### **ENDS**

This ASX announcement was authorised for release by the Board of AusCann.

### **For more information, please contact:**

Layton Mills  
Chief Executive Officer  
info@auscann.com.au  
+61 8 6305 0705

## **ABOUT AUSCANN**

**AusCann Group Holdings Limited** (ASX:AC8) is an Australian-based company focused on the development and commercialisation of cannabinoid-derived therapeutic products to address unmet needs for humans and animals within Australia and internationally. Our key difference is the commitment to rigorous product development, focused on providing reliable, stable and standardised cannabinoid-derived therapeutics products, whilst generating robust safety, quality assurance and efficacy data to support market access in various regulatory environments around the world. Further information is available at [www.auscann.com.au](http://www.auscann.com.au)